Neurocrine Biosciences
NBIX
NBIX
435 hedge funds and large institutions have $8.45B invested in Neurocrine Biosciences in 2022 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 156 increasing their positions, 158 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
435
Holders Change
+11
Holders Change %
+2.59%
% of All Funds
7.36%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.15%
New
62
Increased
156
Reduced
158
Closed
43
Calls
$111M
Puts
$36.6M
Net Calls
+$74.3M
Net Calls Change
+$64.2M
Top Buyers
| 1 |
Holocene Advisors
New York
|
+$67.5M |
| 2 |
DM
Deerfield Management
New York
|
+$34.6M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$34.1M |
| 4 |
BlackRock
New York
|
+$31.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$30.9M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$107M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$63.5M |
| 3 |
Two Sigma Investments
New York
|
-$33.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.4M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28.1M |
